A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Ceritinib (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 21 Jun 2017 Planned primary completion date changed from 11 Jun 2017 to 11 Sep 2017.
- 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2018.
- 28 Jul 2015 Patient exclusion criteria been amended.